EMA panel adopts positive opinion of Vemlidy for treatment of HBV in adults, adolescents

Vemlidy, a drug to treat chronic HBV patients, has receive positive opinion from the EMA’s Committee for Medicinal Products for Human Use. Patients only require a 25mg dose of this powerful medicine, in which is less than 1/10th the amount of another well-known medication.

Learn more all about it here: bit.ly/2frS6yf